Jazz Pharmaceuticals (JAZZ) – Investment Analysts’ Weekly Ratings Changes

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

• 6/10/2026 – Jazz Pharmaceuticals had its price target raised by Bank of America Corporation from $281.00 to $307.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Jazz Pharmaceuticals had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 6/9/2026 – Jazz Pharmaceuticals was given a new $256.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 5/27/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $234.00 to $253.00. They now have an “overweight” rating on the stock.
• 5/26/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/22/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $232.00 to $301.00. They now have an “overweight” rating on the stock.
• 5/21/2026 – Jazz Pharmaceuticals is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $229.00 price target on the stock.
• 5/21/2026 – Jazz Pharmaceuticals was upgraded by Sanford C. Bernstein to “hold”.
• 5/19/2026 – Jazz Pharmaceuticals was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $307.00 price target on the stock, up from $188.00.
• 5/7/2026 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $245.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $239.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $220.00 to $275.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals was given a new $252.00 price target by Robert W. Baird.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $225.00 to $234.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Royal Bank Of Canada from $195.00 to $258.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $250.00 to $265.00. They now have an “overweight” rating on the stock.
• 4/22/2026 – Jazz Pharmaceuticals had its price target raised by Leerink Partners from $215.00 to $225.00. They now have an “outperform” rating on the stock.
• 4/20/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $224.00 to $225.00. They now have an “overweight” rating on the stock.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This represents a 9.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares in the company, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 10,741 shares of company stock worth $2,287,143. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.